Beneficial Effects of Coenzyme Q10 Supplementation on Lipid Profile and Intereukin‑6 and Intercellular Adhesion Molecule‑1 Reduction, Preliminary Results of a Double‑blind Trial in Acute Myocardial Infarction

Abstract

Background: The present investigation was aimed to improve the inflammatory factors and lipoproteins concentration in patients with myocardial infarction (MI) by supplementation with coenzyme Q10 (CoQ10).

Methods: In a double‑blind, placebo‑controlled study, we measured serum concentrations of one soluble cell adhesion molecules (intercellular adhesion molecule‑1 [ICAM‑1]), serum concentration of intereukin‑6 (IL‑6) and lipid profiles (high‑density lipoprotein‑cholesterol [HDL‑C], low‑density lipoprotein‑cholesterol [LDL‑C], total cholesterol and triglyceride [TG]) in CoQ10 supplementation group (n = 26) compared with placebo group (n = 26) in hyperlipidemic patients with MI. Fifty‑two patients were randomized to receive 200 mg/day of CoQ10 or placebo for 12 weeks.

Results: There were no significant differences for serum LDL‑C, total cholesterol, and TG between two mentioned groups after the intervention. Asignificant enhancement in serum HDL‑C level was observed between groups after the intervention (55.46 ± 6.87 and 44.07 ± 6.99 mg/dl in CoQ10 and placebo groups, respectively P < 0.001).Concentrations of ICAM‑1 (415.03 ± 96.89 and 453.38 ± 0.7 ng/dl CoQ10 and placebo groups, respectively, P= 0.001) and IL‑6 (11 ± 9.57 and 12.55 ± 8.76 pg/ml CoQ10 and placebo groups, respectively P = 0.001) in serum were significantly decreased in CoQ10 group.

Conclusions: Supplementation with CoQ10 in hyperlipidemic patients with MI that have statin therapy has beneficial effects on their aspects of health.

Keywords: Coenzyme Q10, intercellular adhesion molecule‑1, intereukin‑6, lipoprotein, myocardial Infarction